4D Molecular Therapeutics Inc
(NAS:FDMT)
$
21.005
0.06 (0.29%)
Market Cap: 1.09 Bil
Enterprise Value: 574.29 Mil
PE Ratio: 0
PB Ratio: 1.79
GF Score: 62/100 4D Molecular Therapeutics Inc (FDMT) Transcripts
- 4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call TranscriptFeb 05, 2024
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call TranscriptNov 01, 2023
- 4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- 4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- 4D Molecular Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call TranscriptJun 07, 2023
- 4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- 4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- 4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call TranscriptApr 27, 2023
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call TranscriptFeb 22, 2023
- 4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call TranscriptNov 14, 2022
- 4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call TranscriptNov 03, 2022
- 4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- 4D Molecular Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call TranscriptOct 25, 2021
- 1